State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL

被引:31
作者
Bernardi, Stella [2 ,3 ]
Secchiero, Paola [2 ,3 ]
Zauli, Giorgio [1 ]
机构
[1] IRCCS BurloGarofolo Trieste, Inst Maternal & Child Hlth, I-34100 Trieste, Italy
[2] Univ Ferrara, Dept Morphol & Embryol, I-44100 Ferrara, Italy
[3] Univ Ferrara, LTTA Ctr, I-44100 Ferrara, Italy
关键词
Apoptosis; apoptosis resistance; combination therapy; death receptors agonists; extrinsic apoptotic pathway; safety; TRAIL; TRAIL mimetics; APOPTOSIS-INDUCING LIGAND; NF-KAPPA-B; AGONISTIC MONOCLONAL-ANTIBODY; DRUG-INDUCED APOPTOSIS; CELL LUNG-CANCER; DEATH-RECEPTOR; PHASE-I; MEDIATED APOPTOSIS; TUMOR-CELLS; CARCINOMA-CELLS;
D O I
10.2174/157489212799972927
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multicellular organisms require apoptosis whereby the human body eliminates unnecessary and/or damaged cells. Apoptosis, or programmed cell death, can indeed be considered as a constitutive anti-cancer mechanism that seems to be defective in more than 50% of cancers. Molecular insights on the biology of the apoptotic process have led to the development of new anti-cancer strategies aiming at recovering and stimulating this process. Preclinical and clinical studies of our and other groups have demonstrated that targeting the extrinsic apoptotic pathway by various death receptors agonists is a safe and effective anti-cancer strategy, which thus may become a new cornerstone of cancer therapy. Here, we review the most recent acquisitions and patents on TRAIL or TRAIL mimetics, as well as the combination therapies that could be used with them.
引用
收藏
页码:207 / 217
页数:11
相关论文
共 143 条
[1]  
Adams C.W, 2006, Patent No. [US20060269554, 20060269554]
[2]   Bcl-2-regulated apoptosis: mechanism and therapeutic potential [J].
Adams, Jerry M. ;
Cory, Suzanne .
CURRENT OPINION IN IMMUNOLOGY, 2007, 19 (05) :488-496
[3]  
Adida C, 1998, AM J PATHOL, V152, P43
[4]  
Alnemri E.S, 2001, Patent No. [US20020132786, 20020132786]
[5]   Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ [J].
Arnt, CR ;
Chiorean, MV ;
Heldebrant, MV ;
Gores, GJ ;
Kaufmann, SH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (46) :44236-44243
[6]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[7]  
Ashkenazi A.J., 2008, Patent No. [US20080182277, 20080182277]
[8]  
Ashkenazi A.J., 2001, Patent No. [US6252050, 6252050]
[9]  
Ashkenazi A.J, 2000, Apo-2 ligand, Patent No. [US6030945, 6030945]
[10]   Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL) [J].
Ashkenazi, Avi ;
Holland, Pamela ;
Eckhardt, S. Gail .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3621-3630